Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSLE)

Satellos Bioscience Inc (MSLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,744
  • Shares Outstanding, K 15,459
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,870 K
  • EBIT $ -19 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 2
  • High Estimate $-0.36
  • Low Estimate $-0.57
  • Prior Year $-0.48
  • Growth Rate Est. (year over year) +2.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.63 +4.26%
on 03/31/26
13.39 -56.18%
on 03/03/26
-7.14 (-54.88%)
since 03/02/26
3-Month
5.63 +4.26%
on 03/31/26
13.39 -56.18%
on 03/03/26
-0.33 (-5.31%)
since 01/02/26
52-Week
4.53 +29.61%
on 06/16/25
13.39 -56.18%
on 03/03/26
-0.37 (-5.93%)
since 04/02/25

Most Recent Stories

More News
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP,...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)

Business Summary

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience...

See More

Key Turning Points

3rd Resistance Point 6.18
2nd Resistance Point 6.09
1st Resistance Point 5.98
Last Price 5.87
1st Support Level 5.78
2nd Support Level 5.69
3rd Support Level 5.58

See More

52-Week High 13.39
Fibonacci 61.8% 10.01
Fibonacci 50% 8.96
Fibonacci 38.2% 7.92
Last Price 5.87
52-Week Low 4.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.